169 results on '"Teixido, C."'
Search Results
2. Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group
3. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution
4. Análisis de pacientes con diabetes tipo 2 en un centro de salud urbano. Estudio DESENROQUE
5. MA14.08 Pathogenic Germline Variants in Patients with Non-Small Cell Lung Cancer (NSCLC) Detected by Tissue Comprehensive Genomic Profiling
6. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
7. 152P Role of occupation in patients with non-small cell lung cancer (NSCLC) in Spain: Data from the SCAN study
8. EP08.02-102 Feasibility and Clinical Utility of ctDNA for Detection of Sensitizing and Resistance EGFR Mutations in Patients with Non-small Cell Lung Cancer
9. 1659TiP A Spanish observational study for MOLecular characterization of THYroid carcinoma: MOLTHY Project – TTCC-2020-02
10. MA07.07 Clinical/Molecular Profile of Patients with Non-small Cell Lung Cancer (NSCLC) with Incidental Pathogenic Germline Variants Detected in cfDNA
11. OA13.04 Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study
12. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
13. 1594P Cancer mortality in young population and estimated radon areas in Spain
14. 1577P Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
15. 1356P Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysis
16. 1282P Activity of brigatinib based on genomic alterations detected on ctDNA at baseline and at progression in ALK inhibitor-naïve advanced ALK+ NSCLC from the ALTA-1L trial
17. 138P Prevalence and characteristics of lung cancer in families harboring pathogenic germline variants in cancer predisposing genes
18. Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group
19. MA14.02 RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study
20. 1268P Real-time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC
21. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution
22. Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer
23. 2220P MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
24. 1278P ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain
25. 1450P Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
26. 182P Impact of SARS CoV 2 outbreak in the molecular diagnosis of advanced NSCLC: A retrospective comparative cohort study
27. Preliminary Report of a Multidisciplinary Task Group for the Study of Immune-Mediated Pulmonary Toxicity
28. Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
29. Comprehensive characterization of MET alterations in a large cohort of 610 advanced non-small cell lung cancer patients
30. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study
31. EP1.01-41 Feasibility of EBUS-TBNA Cytologies for an Extensive Assessment of Predictive Biomarkers in Lung Cancer
32. P1.01-43 Programmed-Death Ligand 1 Spectrum in a Large Cohort of Genetically Characterized Non-Small Cell Lung Cancer Patients
33. P2.03-17 Optimization of an Ex-Vivo Preclinical Model for Drug Testing
34. P2.04-61 Preliminary Report of a Multidisciplinary Task Group for the Study of Immune-Mediated Pulmonary Toxicity
35. P2.04-22 Programmed Death 1-mRNA Expression Predicts Benefit to Anti-PD1 Monotherapy in a Prospective Cohort of Advanced NSCLC
36. P1.01-56 Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
37. Interferon-Gamma (INFG) as a Biomarker to Guide Immune Checkpoint Blockade (ICB) in Cancer Therapy
38. P09.28 Access to Intermediate and Intensive Care for Patients With Lung Cancer During the COVID-19 Period
39. P09.15 Severity of Lung Cancer Disease in Hospitalized Patients During COVID-19
40. MA03.08 Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer
41. P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients
42. An international platform representing expectations and experiences of young investigators in cancer research - [VI:N]
43. Microemulsions and the Treatment of Oil Spills
44. P1.07-015 Interferon-Gamma (INFG) as a Biomarker to Guide Immune Checkpoint Blockade (ICB) in Cancer Therapy
45. P3.01-045 Correlation of EGFR Mutation Detection in CtDNA by Two Different Platforms in Advanced NSCLC Patients from a Single Institution
46. Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC)
47. Prédiction épigénétique du bénéfice clinique avec les anti-PD-1 dans le traitement des cancers du poumon non à petites cellules avancées : une étude internationale multicentrique rétrospective
48. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation
49. P3.04-16 A Seven-Gene Expression Signature Reveals Unique Immune-Phenotypes Related to Major Oncogenic-Drivers in NSCLC
50. P3.04-13 PD-L1-Gene Expression by nCounter Correlates with PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.